Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
1 drugs in development
By Therapeutic Area
top 0
No TA breakdown available.
R&D Momentum
46/100
Pipeline Velocity
11/100
Trial Completion Rate
86/100
Pipeline Concentration
100/100
Pipeline Freshness
0/100
Activity
Last 14 days
Characterization of Diseases With Salivary Gland Involvement
Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Disease Phase IIa Open-Label Clinical Trial and Associated Mechanistic Studies
The Pathogenesis and Natural History of Sjogren's Disease
A Natural History Study of Bone and Mineral Disorders
Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome
Oral Specimen and Data Acquisition Study of Subjects Requiring Third Molar Removal
Oral Microbial and Immunological Characterization of Patients With Immune Dysfunction
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)